This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

OKYO Pharma Croissance future

Future contrôle des critères 3/6

OKYO Pharma is forecast to grow earnings and revenue by 109.7% and 149.8% per annum respectively while EPS is expected to grow by 147.9% per annum.

Informations clés

109.7%

Taux de croissance des bénéfices

147.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	35.4%
Taux de croissance des recettes	149.8%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	16 Feb 2023

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:OK10 - Estimations futures des analystes et données financières antérieures (GBP Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2025	13	6	4	4	1
3/31/2024	N/A	-7	-6	-6	1
3/31/2023	N/A	-13	-8	-8	N/A
12/31/2022	N/A	-11	-7	-7	N/A
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-5	-4	-4	N/A
3/31/2022	N/A	-5	-5	-5	N/A
12/31/2021	N/A	-5	-5	-5	N/A
9/30/2021	N/A	-4	-3	-3	N/A
6/30/2021	N/A	-3	-2	-2	N/A
3/31/2021	N/A	-3	-2	-2	N/A
12/31/2020	N/A	-1	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-1	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-4	-2	-2	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-4	-2	-2	N/A
12/31/2018	N/A	-3	N/A	N/A	N/A
9/30/2018	N/A	-2	-2	-2	N/A
6/30/2018	N/A	-11	-1	-1	N/A
3/31/2018	N/A	-20	-1	-1	N/A
12/31/2017	N/A	-20	-1	-1	N/A
9/30/2017	N/A	-19	-1	-1	N/A
6/30/2017	N/A	-10	-1	-1	N/A
3/31/2017	N/A	0	-1	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A
9/30/2016	N/A	0	N/A	0	N/A
6/30/2016	N/A	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	0	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-4	N/A	-1	N/A
9/30/2014	N/A	-3	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A
12/31/2013	N/A	-8	N/A	-2	N/A
9/30/2013	N/A	-8	N/A	-2	N/A
6/30/2013	N/A	-5	N/A	-2	N/A
3/31/2013	N/A	-3	N/A	-3	N/A
12/31/2012	N/A	-3	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: OK10 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Bénéfices vs marché: OK10 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: OK10 is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: OK10 is forecast to have no revenue next year.

Croissance élevée des revenus: OK10 is forecast to have no revenue next year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if OK10's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

OKYO Pharma Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance